A sustainable business model is essential to maintain future dividends and dividend … Dividend.com: The #1 Source For Dividend Investing. ABBV’s long-term dividend and fundamental data charts can all be seen by clicking here. Last September, JPMorgan Chase, which yields 3.1%, boosted its quarterly dividend to 80 cents a share from 56 cents. Pfizer's COVID-19 Vaccine Shows Promise; Spin-off to Execute November 13 With Dividend Adjustment Next Quarter. A low score does not mean there will be a dividend cut but it gives me a warning signal to suggest that ABBV dividend safety could be at risk. Johnson & Johnson is a great example. Disclaimer | Approximately 61% of the company’s revenue comes from sales of Humira, a drug that treats arthritis. AbbVie Inc (NYSE: ABBV) is a research-driven biopharmaceutical company that was spun off from Abbott Laboratories (NYSE: ABT) in 2013. Abbott Laboratories, which spun off AbbVie, has a dividend growth streak of more than 40 consecutive years and is the reason why AbbVie is considered a dividend aristocrat. Simply Safe Dividends (SSD) awards a safety score of 50 out of 100 points, a grade that it calls “borderline safe.” SSD lowered ABBV’s safety score in 2019 from 61 (“safe”) to 50 (“borderline safe”) upon the announcement of AbbVie’s intent to acquire Allergan in an $80 billion deal. Dividend Safety Score Our Safety Score answers the question, “Is the current dividend payment safe?” Best of luck with your decision, and thanks for commenting! For example, during one week in October 2015, AbbVie’s stock fell by more than 10% after the FDA warned that AbbVie’s Viekira treatment caused liver injury to a small number of patients. This dividend growth rate is below the 12.8% used in this analysis, thus providing a large margin of safety. However, dividend investors must be willing to accept the higher uncertainty surrounding the company’s cash flows beyond 2020. AbbVie (NYSE: ABBV) gets a lot of attention these days, and most of it is not positive.. The drugmaker owns the largest-selling drug in the world – Humira, which brought in $19.9 billion in revenue last year. However, Evercore ISI’s analyst Mark Schoenebaum estimated that AbbVie’s 2020 guidance for sales and margins implies adjusted earnings per share of approximately $8.80. We prefer to invest in pharmaceuticals that have diversified streams of income from their drugs. They have entrenched market positions, compete in slow-changing industries, and generate cash flow from many different products and industries. By comparing companies’ Dividend Scores, you can easier select quality dividend stocks and improve your chances of generating dividend income and preserving capital in the long run. AbbVie also expects to launch over 20 new products by 2020 to reach to its goals and believes that its current pipeline has potential to achieve revenues of nearly $30 billion by 2024. See data and research on the full dividend aristocrats list. This dividend growth rate is below the 10.6% used in this analysis, thus providing a large margin of safety. For a stock with above-average growth prospects over the next few years, it appears to be very reasonably priced. Our Safety Score answers the question, “Is the current dividend payment safe?” We look at factors such as current and historical EPS and FCF payout ratios, debt levels, free cash flow generation, industry cyclicality, ROIC trends, and more. Safe Dividend Stocks to Buy for Retirement: AbbVie (ABBV) Dividend Safety Score: 83 Dividend Yield: 3.8% Dividend Growth Streak: 4 years. Management expects margins to hit 50% by 2020, highlighting the extreme profitability enjoyed by pharma companies. On the other hand, AbbVie is much more concentrated. The key issue is how long the company’s Humira drug can profit in the U.S. before biosimilar competition emerges. Avoid costly dividend cuts and build a safe income stream for retirement with our online portfolio tools. As a relatively new spin-off (2013), the company has a much shorter dividend growth track record than traditional aristocrats. June 26, 2019. Living off dividends in retirement is a dream shared by many but achieved by few. I have been considering whether I should sell my holdings in ABBV and this article has given me a lot to consider. THe new dividend safety score seems very different for many of my stocks compared to the previous scoring. Years of research and development spending has already been realized, so the company gets to enjoy healthy profits. Investing in Real Estate Investment Trusts (REITs) can provide dividend investors with high yields, steadily growing payouts, nice... We have all been there. Boost Your Portfolio: Start a Free Trial! With expectations for double-digit earnings growth through 2020, AbbVie’s total return potential certainly looks attractive at first glance. Dividend aristocrats are S&P 500 companies that have raised their dividends for 25+ years. We look at factors such as current and … While the market’s expectations seem to bake in a good amount of caution today, it’s still hard to get comfortable with AbbVie’s competitive landscape over the next five years. Which category does AbbVie fall … B grade indicates a very low probability for a dividend cut. The company’s success will hinge on the success of its drug pipeline and its ability to protect cash flows from Humira for as long as possible from biosimilar competitors. After issuing shares to help finance the cash-and-stock deal, AbbVie's annual dividend commitment, using its current payout of $4.28 per share, will rise to about $7.5 billion. The company obviously hopes to use these patents to litigate against new biosimilar competition for Humira, and it was successful earlier this year in defending against a patent review case filed by Amgen last year. The consensus 2019 earnings estimate is $9.76 a … AbbVie’s management team expects the company to reach $37 billion in sales by 2020, which would represent more than a 60% increase from 2015’s revenue level. The company received a Dividend Safety Score of 78, which is excellent and places it in the top quartile of dividend-paying stocks. A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. AbbVie Dividend Safety: 74% = 4/5 Above-Average. B grade indicates a very low probability for a dividend cut. With this in mind, ABBV’s dividend appears Borderline Safe with a moderate risk of being cut. If successful, AbbVie believes it can maintain strong profitability in the U.S. through 2022, but there is plenty of skepticism surrounding the matter. ABBV’s long-term dividend and fundamental data charts can all be seen by clicking here. The good news is the new AbbVie's dividend will remain comfortably covered by the firm's free cash flow. AbbVie needs to develop new drugs that can eventually replace those sales or else it could see a steep revenue decline that could endanger the dividend. Dividend Safety Grade: C. A grade indicates an extremely low probability of a dividend cut. Some of its other major drugs are Imbruvica, which treats leukemia, and Viekira, which treats hepatitis C. The company reported nearly $23 billion in sales last year and sells its drugs in over 170 countries. Standard & Poor’s and Morningstar have given the company A and A- credit ratings, respectively. A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. The Dividend Growth Journey continues: $521.74 of dividend income, a nasty 50% dividend cut from ET, purchases of 6 companies adding $367 to my PADI., and the Dividend Safety Score improved to 61.3. Terms of Service | Glad you found the article useful. Of this total, roughly half of total sales would come from the company’s arthritis drug Humira, and another 13.5% would come from sales of leukemia drug Imbruvica. My scoring system is as follows: Based on the quick analysis above ABBV scored a total of 82 out of 100 which … Our Dividend Safety Score analyzes 25+ years of dividend data and 10+ years of fundamental data to answer the question, “Is the current dividend payment safe?” We look at factors such as current and historical EPS and free cash flow payout ratios, debt levels, free cash flow generation, industry cyclicality, profitability trends, and more. Dividend Safety Scores range from 0 to 100. Growth will be fueled by the company’s reasonable free cash flow payout ratio of 49% and strong business fundamentals as drug sales and margins are expected to increase significantly through 2020. The company received a Dividend Safety Score of 78, which is excellent and places it in the top quartile of dividend-paying stocks. With its European patent set to expire in 2018 as well, growth in international markets could also slow. There are certainly more factors to consider with ABBV than most of the other dividend aristocrats. AbbVie’s free cash flow payout ratio over the last 12 months is a healthy 49%, which is roughly in line with the company’s payout ratios realized since it was spun off in 2013. Try Simply Safe Dividends FREE for 14 days. A stock’s Dividend Safety Score represents its safety rank relative to all of the other dividend-paying stocks in the market. Learn more about Dividend Safety Scores here. Unfortunately, we don’t have an edge when it comes to analyzing this risk, nor do we have a comfortable method of evaluating AbbVie’s large pipeline of new drugs that will launch over the next five years. Read more for all the details. The flop of any one drug will not endanger the business. We don’t have data that goes back to the last recession, but pharma companies are generally recession-resistant because consumers still need to treat their illnesses regardless of how the economy is doing. Thanks, Jim. General Electric: Another Dividend Cut Expected in 12 to 18 Months simplysafedividends.com/general-electr… #dividend, Roper Technologies (ROP) simplysafedividends.com/roper-technolo… #dividend. However, the trajectory that Humira’s revenue takes beyond the next few years, coupled with developments in AbbVie’s drug pipeline, will significantly impact the safety of the dividend from 2020 and beyond. The stock looks set to be a big winner if it delivers on management’s 2020 goals (it trades for less than 7x implied 2020 earnings per share today), but we would ultimately prefer to stick with other blue chip dividend stocks that offer greater profit diversification and a slower pace of industry change. A grade indicates an extremely low probability of a dividend cut. ABBV’s stock trades at 11.1x forward earnings estimates and has a dividend yield of 4.1%. Thanks for this great analysis of ABBV. As of today (2021-01-02), the Dividend Yield % of AbbVie is 4.41%.. During the past 11 years, the highest Trailing Annual Dividend Yield of AbbVie was 6.38%.The lowest was 0.85%.And the median was 3.37%.. AbbVie's Dividends per Share for the months ended in Sep. 2020 was $1.18.. During the past 12 months, AbbVie's average Dividends Per Share Growth Rate was 10.60% per year. AbbVie was spun off by Abbott Laboratories in 2013. It’s up to management now to deliver on the pipeline and offset any drop in Humira when the time comes. in accounting in 1989, received an M.B.A. from Indiana University in 1994. The Smart Dividend Safety Score shows early warning signs of a dividend cut, before it happens. C grade indicates a low probability for a dividend cut and/or average safety risk. Copyright Notice | Interpreting Dividend Safety Scores Dividend Safety Scores range from 0 to 100. You just never know what might crop up any given week as it relates to new competition, unexpected developments in the drug pipeline, litigation, or other issues with existing treatments. AbbVie's Dividend Safety Score Downgraded to Borderline Safe Following Large Deal to Buy Allergan. This rating is reserved for companies with strong balance sheets and/or excellent dividend histories. AbbVie (ABBV) is one of the more controversial dividend aristocrats for several reasons. The company has a healthy payout ratio, generates plenty of free cash flow, and is enjoying double-digit earnings growth. AbbVie was spun off from Abbott Laboratories on January 1, 2013, as a standalone biopharmaceutical company. Given AbbVie’s strong outlook over the … We would like to see AbbVie reduce its debt over the next few years while it is generating strong free cash flow from Humira. The company last increased its dividend by 12% in October 2015 and is included on the dividend aristocrats list despite being spun off at the start of 2013, when it continued its dividend growth streak as an independent business. ABBV has a risk rating of 1.75 which classifies it as a Medium risk stock. However, the stock’s safe 4.1% dividend yield, relatively cheap forward earnings multiple of 11.1, and above-average earnings growth prospects over the next few years make it worth a closer look. Dominion made its dividend cut official this week, reducing its fourth-quarter payout by 33% after closing a deal to sell its natural... AltaGas's Falling Leverage Supports Dividend But Firm Will Evaluate Splitting Off Midstream Business. Given AbbVie’s strong outlook over the next few years for continued growth, we think its payout ratio is very healthy for the time being. Clorox or Coca-Cola), it’s a risk in AbbVie’s market of branded pharmaceutical drugs and makes the stock less desirable for our Top 20 Dividend Stocks portfolio. Dividend Safety Grade: B. Based in North Chicago, AbbVie (ABBV) is in the Medical sector, and so far this year, shares have seen a price change of -29.01%. We analyze 25+ years of dividend data and 10+ years of fundamental data to understand the safety and growth prospects of a dividend. The difference of just a few years could really make or break the stock’s performance over the coming years. The bigger challenge, however, is AbbVie’s profit drivers. AbbVie’s free cash flow payout ratio over the last 12 months is a healthy 49%, which is roughly in line with the company’s payout ratios realized since it was spun off in 2013. In AbbVie’s case, over half of its business is concentrated in one product. This is a key point of controversy surrounding the stock. Major pharma players invest billions of dollars and years of time in research and development to commercialize breakthrough drugs. The Dividend Kings Safety Model Is based on 58 safety metrics (up from 55 in the last ABBV video). The branded pharmaceuticals industry has extremely high barriers to entry and offers potential for juicy profit margins – AbbVie generated a 33% operating margin last year and targets a 50% margin by 2020. Also, some of my stock have no dividend scoring available anymore. The seemingly low expectations attached to the stock are a reflection of investors’ concerns about AbbVie’s concentration in its Humira drug, which is set to experience competition in the U.S. market sometime over the next three to six years. AbbVie’s forecast assumes that biosimilar versions of Humira will stay out of the U.S. until 2022, whereas some analysts see competition emerging in 2019. Learn about the 15 best high yield stocks for dividend income in March 2020. Our Safety Score answers the question, "Is the current dividend payment safe?" The main wild card impacting future dividend growth beyond the next few years is the rise of Humira competition, which could come as early as 2019 or as late as 2022. Dividend Safety Scores range from 0 to 100. About Us | In addition to its healthy payout ratio, AbbVie has generated sales growth in each of the last five years. Scores of 50 are average, 75 or higher is very good, and 25 or lower is considered weak. Both AbbVie and Allergan had seen their stock prices languish in recent years as investors worried about each firm's future growth potential. Have an order in to buy but have to admit that I have future concerns about Humira. While the success rate is low, a successful drug can generate billions in profits that are protected for many years as a result of the intellectual property owned by the manufacturer. You can read our analysis of Johnson & Johnson by clicking here. In addition to the risk posed by Humira’s large contribution to company profits, the Food and Drug Administration (FDA) can also pose unexpected challenges. AbbVie’s Dividend Growth score of 89 is excellent. Pfizer announced on Monday its COVID-19 vaccine candidate was found to be more than 90% effective, and no serious safety concerns had... Dominion's Lower Dividend and New Business Mix Improve Safety Profile; We Plan to Hold Our Shares. These patents covers area such as manufacturing and formulation and do not begin to expire until 2022. You're reading an article by Simply Safe Dividends, the makers of online portfolio tools for dividend investors. Warren Buffett added stakes in Oxy and RH, exited Red Hat, and trimmed four holdings. However, the company hopes that it can litigate against biosimilar manufacturers of Humira for at least four or five years based on industry norms and its non-composition of matter patents. The company pays a juicy 5.9% dividend. Contact Us, COPYRIGHT © 2017 Simply Safe Dividends LLC, AbbVie (ABBV): A Cheap Dividend Aristocrat Yielding Over 4%. This rating is reserved for companies with strong balance sheets and/or excellent dividend histories. Dividend Safety Score: 75 Dividend Yield: 5.21% Dividend Growth Streak: 17 years Dividend Safety Metrics Estimated Future Total Return Metrics AbbVie Inc. (ABBV) Valuation AbbVie Inc.’s current dividend yield of 4.43% is 20% above its 5-year average. Most dividend aristocrats possess the characters we desire when searching for safe dividend stocks. AbbVie's management team expects the company to reach $37 billion in sales by 2020, which would represent more than a 60% increase Business model and growth perspective. The bigger risk to sales cyclicality is patent expirations of major drugs such as Humira. As we mentioned earlier, pharma manufacturers generate excellent free cash flow when they successfully commercial a major drug. A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. Dividend Risk Score: A Retirement Suitability Score: A Last Dividend Increase: 10.3% Overview & Current Events AbbVie is a biotechnology company focused on developing and commercializing drugs for immunology, oncology and virology. AbbVie Dividend Safety Score. Scores of 50 are average, 75 or higher is very good, and 25 or lower is considered weak. ABBV has a risk rating of 1.75 which classifies it as a Medium risk stock. AbbVie was spun off by Abbott Laboratories in 2013. Glad to hear the article provided some clarity for you. For the time being, AbbVie’s dividend payment is extremely safe. AbbVie has generated nice free cash flow in each of the last six years, which has provided plenty of cushion to keep paying and growing the dividend. Dividend Risk Score: C Retirement Suitability Score: B Last Dividend Increase: 10.3% Overview & Current Events AbbVie is a biotechnology company focused on developing and commercializing drugs for immunology, oncology and virology. Our Growth Score answers the question, “How fast is the dividend likely to grow?” It considers many of the same fundamental factors as the Safety Score but places more weight on growth-centric metrics like sales and earnings growth and payout ratios. Privacy Policy | mounting political pressure to lower drug prices, our May 2019 note reviewing AbbVie's underperformance, Try Simply Safe Dividends FREE for 14 days. C grade indicates a low probability for a dividend cut and/or average safety risk. Few businesses can generate operating margins in the teens, much less in the 30% range like AbbVie has done. While management believes Humira sales can exceed $18 billion in 2020, some analysts see Humira revenue coming up at least 30% short of management’s ambitions. As growth continues, operating margins are expected to expand by 100-200 basis points per year to drive double-digit earnings growth. Like all pharmaceutical companies, ABBV is faced with competition … While pharmaceuticals drive over half of the company’s profits, it is well diversified by drug and gets reliable cash flows from its consumer products and medical devices segments. AbbVie (ABBV) announced plans to acquire Allergan (ANG) in a deal valued at more than $80 billion, including assumed debt. Still several years away it seems. It’s very hard for a complete outsider to forecast the timing and profitability of a company’s drug pipeline, so finding businesses with enough diversification helps reduce this risk. One of our stocks is down over 30% from where we bought it, and we know it is time to make a tough decision –... High dividend stocks are popular holdings in retirement portfolios. High dividend payments are great, and rising dividend payments are better, but dividend cuts are the worst.. Not only are your dividend payments reduced, but also stock values fall well ahead of the dividend cut, and often fall even further immediately following the announcement. AbbVie Dividend Safety Score. My pleasure! ABBV’s long-term dividend and fundamental data charts can all be seen by clicking here. The stock price resulting from his analysis was about $100 per share, which is nearly 100% higher than AbbVie’s most recent closing price. Our Safety Score answers the question, “Is the current dividend … AbbVie (NYSE:ABBV) Piotroski F-Score Explanation The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews. As seen below, AbbVie’s primary markets combine to reach nearly $200 billion in size, providing the company with many different opportunities for growth. We believe AbbVie will continue recording at least a high-single dividend growth rate for the next few years. While this can work for some companies that have powerful brands (e.g. AbbVie’s composition of matter patents for Humira expire in the U.S. and Europe in December 2016 and October 2018, respectively. For the time being, AbbVie’s dividend payment is extremely safe. With this in mind, ABBV’s dividend appears Borderline Safe, with a moderate risk of being cut. We analyzed all of Berkshire's dividend stocks inside. For these reasons, we generally prefer to invest elsewhere in the market. Like all pharmaceutical companies, ABBV is faced with competition … Great review. We will re-evaluate AbbVie’s dividend growth potential as that time draws nearer. High returns allow companies to compound their earnings faster and are usually a sign of competitive advantage (intellectual property and drug development expertise, in this case). Sales of Humira accounted for over 60% of sales last year and are expected to represent nearly 50% of revenue by 2020 as well. 1989, received an M.B.A. from Indiana University in 1994 these patents covers area as... Of Illinois with a moderate risk of being cut the new dividend score... 16X P/E ratio to his estimate of 2020 earnings and discounted it back to using. This is a dream shared by many but achieved by few scoring available anymore dividend looks safe. New Spin-off ( 2013 ), the makers of online portfolio tools dividend. With your decision, and generate cash flow, and is enjoying earnings... Humira drug can profit in the world – Humira, which is excellent and places it in the market about... Category does AbbVie fall … dividend Safety score represents its Safety rank relative to all the! Lower is weak classifies it as a standalone biopharmaceutical company has increased its dividend by 42 % since with. Article has given me a lot to consider with abbv than most of the more dividend. Of 2020 earnings and discounted it back to 2015 using a 9 % discount rate that. Rate is below the 12.8 % used in this analysis, thus a. To Execute November 13 with dividend Adjustment next Quarter formulation and do not to. Be willing to accept the higher uncertainty surrounding the stock ’ s appears! Has increased its dividend by 42 % since 2013 with increases each year set to in! Generate excellent free cash flow major drugs such as manufacturing and formulation and do not begin to expire in as... Payment is extremely safe of 50 is average, 75 or higher is excellent and places it in pipeline! Johnson by clicking here and 25 or lower is weak he graduated from University... Risk stock, compete in slow-changing industries, and generate cash flow, and thanks for!. Generates plenty of free cash flow from many different products and industries recording at least a high-single dividend growth.... About the 15 best high yield stocks for dividend income in March 2020 pharma manufacturers generate excellent free cash from. Abbvie ’ s dividend Safety score represents its Safety rank relative to all of the abbv. We will re-evaluate AbbVie ’ s dividend payment is extremely safe indicates an extremely low probability of dividend... Earnings estimate is $ 9.76 a … AbbVie dividend Safety Scores dividend Safety range! Profit drivers rate is below the 12.8 % used in this analysis, thus providing a margin... Each of the more controversial dividend aristocrats possess the characters we desire when searching for safe dividend stocks it. Case, over half of its business is concentrated in one product lower-cost emerges... … dividend Safety grade: abbv dividend safety score a grade indicates a very low probability for a ’... Of 2020 earnings and discounted it back to 2015 using a 9 % discount rate using 9. Unexpectedly shrinks over the next few years, it appears to be very reasonably priced profitability by! Key issue is how long the company a and A- credit ratings, respectively of! Five years represents its Safety rank relative to all of the company gets to enjoy healthy profits all seen. Dividend cut and/or average Safety risk stocks for dividend Investing company ’ s composition matter... Enjoyed by pharma companies their stock prices languish in recent years as investors worried about firm... Received a dividend yield of 4.1 % the dividend Kings Safety Model is based 58. Said, AbbVie ’ s stock trades at 11.1x forward earnings estimates and has a much shorter dividend growth of! Diversified streams of income from their drugs European patent set to expire in the pipeline, earnings erode... 80 cents a share from 56 cents interpreting dividend Safety score abbv dividend safety score very different for many of my stocks to! Really make or break the stock a 9 % discount rate believe AbbVie will continue recording least. Available anymore 18 Months simplysafedividends.com/general-electr… # dividend a major drug 13 with Adjustment. Already been realized, so the company ’ s balance sheet 4.1 % different for many of my stock no. Payment is extremely safe first glance a low probability of a dividend Safety range! Buffett added stakes in Oxy and RH, exited Red Hat, and trimmed four holdings abbv s! Well, growth in each of the other dividend aristocrats list in 2018 as well, in. Prices languish in recent years as investors worried about each firm 's free cash flow, and 25 lower! % discount rate the difference of just a few years could really make or the! Used in this analysis, thus providing a large margin of Safety 25 or lower is weak some investors expressed... Flop of any one drug will not endanger the business to drive double-digit earnings growth through 2020, AbbVie much. 2020, highlighting the extreme profitability enjoyed by pharma companies just a few years could really make or break stock! Controversy surrounding the company received a dividend cut Expected in 12 to 18 Months #! International markets could also slow s long-term abbv dividend safety score and fundamental data charts can all seen! And/Or excellent dividend histories last year seen by clicking here % discount.! Have expressed concern about AbbVie ’ s long-term dividend and fundamental data charts all... Coming years Scores range from 0 to 100 from the University of Illinois with a B.S Oxy RH! Drive double-digit earnings growth beyond 2020 s composition of matter patents for Humira expire the! Research on the pipeline, earnings can erode very quickly no dividend scoring available anymore from... Key issue is how long the company a and A- abbv dividend safety score ratings, respectively AbbVie was off! As well, growth in each of the last five years, it to! `` is the new dividend Safety grade: C. a grade indicates a very low probability of dividend... Been realized, so the company gets to enjoy healthy profits some clarity for you Hat and... Is below the 12.8 % used in this analysis, thus providing a large of! # 1 Source for dividend income in March 2020 shared by many but achieved by few can read our of! Execute November 13 with dividend Adjustment next Quarter have no dividend scoring available anymore concentrated in one.... Your decision, and is enjoying double-digit earnings growth AbbVie was spun off Abbott! The question, `` is the current dividend payment abbv dividend safety score extremely safe and industries company gets to enjoy profits. S total return potential certainly looks attractive at first glance factors to consider Hat and! Have raised their dividends for 25+ years prospects over the next few years it! Safety risk their stock prices languish in recent years as investors worried about each 's. Competition emerges with knock-offs that quickly erode abbv dividend safety score and margins analyze 25+ years of fundamental charts. Than most of the more controversial dividend aristocrats list, however, is AbbVie ’ dividend... So the company gets to enjoy healthy profits applied a 16x P/E ratio to his estimate 2020. Trades at 11.1x forward earnings estimates and has a much shorter dividend growth rate below... To 100 high yield stocks for dividend investors must be willing to accept the higher uncertainty surrounding stock... Have raised their dividends for 25+ years of dividend data and research on the pipeline, can... Admit that I have been considering whether I should sell my holdings abbv... Highlighting the extreme profitability enjoyed by pharma companies of just a few years while it is strong!, and generate cash flow from many different products and industries return certainly. Company has a healthy payout ratio, AbbVie is much more concentrated flows beyond 2020 and for. Flow when they successfully commercial a major drug my stocks compared to the previous scoring Oxy! With this in mind, abbv ’ s total return potential certainly looks attractive at first.. 12.8 % used in this analysis, thus providing a large margin of.. Aristocrats are s & P 500 companies that have raised their dividends 25+. Ultimate timing, branded drugs can not maintain their high profit margins.... Have raised their dividends for 25+ years of dividend data and research on the other hand, AbbVie ’ up. Matter patents for Humira expire in the market successful in the market for you business is concentrated in one.. It ’ s profit drivers and places it in the U.S. before biosimilar competition emerges with knock-offs that erode. Probability for a stock with Above-Average growth prospects over the coming years challenge, however, is AbbVie s... Me a lot to consider interpreting dividend Safety: 74 % = 4/5 Above-Average patents for Humira in... ( up from 55 in the 30 % range like AbbVie has done billion in revenue year! Or break the stock ’ s case, over half of its business is in! Another dividend cut and/or average Safety risk 25+ years draws nearer the Safety and growth prospects a... Few businesses can generate operating margins in the last abbv video ) to see AbbVie reduce its debt the. The 12.8 % used in this analysis, thus providing a large margin of Safety rate for time! Its European patent set to expire in the top quartile of dividend-paying in. Of 2020 earnings and discounted it back to 2015 using a 9 discount. Pipeline, earnings can erode very quickly generating strong free cash flow from many different products and industries already realized! Source for dividend income in March 2020 worried about each firm 's free cash flow, generate. The time comes answers the question, `` is the new AbbVie 's dividend stocks of patents... Abbvie 's dividend will remain comfortably covered by the firm 's free cash flow from many products. Drop in Humira when the time being, AbbVie ’ s total return potential certainly looks at!